Imagion Biosystems Limited Provides Update on the Progress of First-In-Human Study for the MagSense HER2 Breast Cancer Imaging Agent
lymph nodes. Currently, nodal staging requires a patient's lymph nodes to be surgically biopsied for histopathological examination. Based on the observations to date, the Company plans to move forward with scale-up activities to support
further development and clinical studies that would support regulatory submissions. If one of the imaging methods is shown to be effective in pivotal studies, the MagSense® HER2 test would be commercialized as a non-invasive alternative reducing the need for biopsies for nodal staging.